Piramal Pharma Solutions Achieves 1,500th ADC Batch Milestone

Piramal Pharma Solutions' facility in Grangemouth, UK, has successfully delivered its 1,500th antibody-drug conjugate (ADC) batch. This achievement signifies its advanced capabilities and reinforces Piramal's leading position in the field of bioconjugate therapies. The milestone is part of their commitment to patient centricity and cutting-edge innovations in oncology.

With over two decades of experience, Piramal has been a pioneer in ADC development. The Grangemouth facility is integral to Piramal's ADCelerate™ program, offering a comprehensive range from proof-of-concept studies to commercial manufacturing. This is supported by strong technical and quality teams that streamline processes across Piramal's global network.

Grangemouth has manufactured hundreds of unique bioconjugates. It maintains a strong regulatory record with accreditations from authorities like the US FDA. Piramal's technical expertise and integrated solutions continue to meet global patient needs with speed and precision.